TEVA-ALENDRONATE/CHOLECALCIFEROL TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
27-07-2017
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
ALENDRONIC ACID (ALENDRONATE SODIUM); VITAMIN D3 (CHOLECALCIFEROL)
Tilgængelig fra:
TEVA CANADA LIMITED
ATC-kode:
M05BB03
INN (International Name):
ALENDRONIC ACID AND CHOLECALCIFEROL
Dosering:
70MG; 5600UNIT
Lægemiddelform:
TABLET
Sammensætning:
ALENDRONIC ACID (ALENDRONATE SODIUM) 70MG; VITAMIN D3 (CHOLECALCIFEROL) 5600UNIT
Indgivelsesvej:
ORAL
Enheder i pakken:
4
Recept type:
Prescription
Terapeutisk område:
VITAMIN D
Produkt oversigt:
Active ingredient group (AIG) number: 0251575002; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2013-03-25
Produktets egenskaber
PRODUCT MONOGRAPH
PR
TEVA-ALENDRONATE/CHOLECALCIFEROL
alendronate sodium/cholecalciferol tablets
70 MG ALENDRONATE + 70 MCG CHOLECALCIFEROL (2800 IU VITAMIN D
3
)
PR
TEVA-ALENDRONATE/CHOLECALCIFEROL
alendronate sodium/cholecalciferol tablets
70 MG ALENDRONATE + 140 MCG CHOLECALCIFEROL (5600 IU VITAMIN D
3
)
Bone Metabolism Regulator and Vitamin D
Teva Canada Limited
Date of Revision:
30 Novopharm Court
July 24, 2017
Toronto, Ontario
M1B 2K9
Canada
Submission Control No: 207329
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
................................................................................................
8
DRUG INTERACTIONS
..............................................................................................
14
DOSAGE AND ADMINISTRATION
..........................................................................
16
OVERDOSAGE
............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 17
STORAGE AND STABILITY
......................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................... 22
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATION
......................................................................
24
CLINICAL TRIALS
.....................................
Læs hele dokumentet
